Wednesday, March 30, 2011
MonoSol Rx receives positive FDA feedback on 505(b)(2) pathway for Montelukast Sodium OSF
MonoSol Rx, the developers of PharmFilm� technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it held a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Montelukast Sodium Oral Soluble Film (OSF) under a 505(b)(2) pathway.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment